Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Deloitte
Baxter
Cantor Fitzgerald
Daiichi Sankyo
Accenture
Julphar
McKinsey
Teva

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

« Back to Dashboard

Clinical Trials for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Trial ID Title Status Sponsor Phase Summary
NCT00039741 Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2/Phase 3 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed PENTA Foundation Phase 2/Phase 3 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2/Phase 3 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00084136 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 4 This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.
NCT00084136 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed AIDS Clinical Trials Group Phase 4 This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 17
HIV 5
HIV-1 Infection 4
HIV Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 24
Acquired Immunodeficiency Syndrome 8
Immunologic Deficiency Syndromes 6
Hepatitis C 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Location Trials
United States 231
Canada 16
Germany 11
Italy 8
United Kingdom 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Location Trials
California 15
New York 12
Illinois 12
Florida 12
North Carolina 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Phase 4 7
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Completed 20
Recruiting 5
Not yet recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Sponsor Trials
Gilead Sciences 14
National Institute of Allergy and Infectious Diseases (NIAID) 10
Merck Sharp & Dohme Corp. 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Sponsor Trials
Industry 33
Other 19
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Baxter
Cantor Fitzgerald
Chinese Patent Office
Daiichi Sankyo
QuintilesIMS
McKesson
Julphar
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.